Pharma BD Deal Intelligence
Watson CEO Paul Bisaro: 'This transaction achieves Watson's stated strategic objective of expanding and diversifying our business into a truly global company.'…
Watson completed the €4.25B acquisition of Actavis on Oct 31, 2012, creating the world's third-largest generics company with pro-forma 2012 revenue >$8B. FTC…
Combined entity achieves top-3 positioning in 11 markets and top-5 in 15 markets globally; ~40% of generics revenues will originate outside the US; deal builds…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Watson Pharmaceuticals acquired Actavis Group for approximately EUR 4.25B (~$5.6-5.9B), creating the world's third-largest generics company with pro forma 2012 revenue of ~$8B. FTC required divestiture of 18 products to Sandoz/Par. Watson later renamed itself Actavis.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc (this deal) | 2012 | $5.9B | 97 |
| Watson Pharmaceuticals (Actavis Inc.) / Arrow Group | 2009 | $1.8B | 85 |
| Watson Pharmaceuticals (Actavis Inc.) / Amarin Development AB (Amarin Corp subsidiary) | 2003 | $150M | 70 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2006 | $1.9B | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Schein Pharmaceutical Inc. | 2000 | $674M | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Eden Biodesign Limited | 2010 | $15M | 63 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2007 | $1.9B | 62 |
← Browse all deals · How we score deals
More: 2012 deals · Watson Pharmaceuticals (Actavis Inc.) deals · Other deals